Investment in First-in-Class antiviral drug development

Synklino is a Danish biotechnology company based in Copenhagen. The company is owned by a group of private shareholders, including family offices and strategic investors.  Members of our board of directors offer in-depth life sciences expertise in all technical, business, and managerial aspects of drug development and licensing. Our Scientific Advisory Board members include Key Opinion Leaders (KOLs) in the field of infectious diseases and transplantation, including:

• Michael Nicholson – Professor of Transplant Surgery at the University of Cambridge and a Consultant Surgeon at Addenbrooke’s Hospital, England. Professor Nicholson is Director of the NIHR Blood and Transplant National Research Unit in Organ Donation and Transplantation. His research group focuses on developing novel renal perfusion technologies with the aim of assessing and reconditioning kidneys and delivering pre-transplant allograft therapies. Professor Nicholson will serve as the Lead Coordinating Investigator in the proposed SYN002 Phase 1 clinical trial that will be conducted in the United Kingdom.

• Camille Nelson Kotton, MD, FIDSA, FAST – Clinical Director of the Transplant Infectious Disease and Immunocompromised Host Program at Massachusetts General Hospital, and Associate Professor of Medicine, Harvard Medical School, Boston. She served as Chair of the Infectious Disease Community of Practice of The American Society of Transplantation from 2012-2018. Dr. Kotton is the first transplant infectious disease specialist to be a councilor of The Transplantation Society (2020). Her clinical interests include vaccinations in transplant candidates and recipients, cytomegalovirus, and travel and tropical medicine in the transplant setting.

Synklino is preparing to enter clinical development with our initial drug candidate, SYN002. We are progressing toward a Phase 1 Clinical Trial in which CMV-infected kidneys will be perfused with SYN002 prior to transplantation. The aim of the trial is to generate safety, pharmacokinetic, and preliminary efficacy data. Our new drug candidate’s competitive advantages stand poised to reshape the landscape of antiviral therapeutics and generate substantial value for our company’s stakeholders, due to:

• The unmet needs of high-risk transplant patients whose treatment options are insufficient to adequately prevent reactivation of CMV and involve associated debilitating side effects;
• SYN002 will be the first treatment targeting latent stage CMV;
• SYN002’s preclinical data, demonstrating promise of being superior to current standard of care treatments and thus having high potential for replacing antivirals;
• Validation by KOLs who have expressed great interest in an innovative pre-transplant prophylactic treatment against CMV;
• Positive interactions with National Regulatory Authorities in Denmark, Spain, and the United Kingdom;
• Our approach to produce SYN002, ensuring cost efficiency and scalability to effectively maximize market reach.